Overview
An Open-Label, Multi-centre, Phase III Study of Local Tolerability of ZOMACTON 10MG
Status:
Completed
Completed
Trial end date:
2006-08-01
2006-08-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Children with growth failure due to inadequate secretion of growth hormone or growth retardation due to Turner's syndrome are individually dosed and treated for 12 weeksPhase:
Phase 3Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Ferring Pharmaceuticals
Criteria
Subjects between the ages of 3 and 17 years (both inclusive) with growth failure due toinadequate secretion of growth hormone or growth retardation due to Turner's syndrome.
Subjects have for a minimum of 6 months prior to study enrolment been receiving growth
hormone therapy